We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Read MoreHide Full Article
In the latest close session, Hims & Hers Health, Inc. (HIMS - Free Report) was down 7.88% at $23.84. This change lagged the S&P 500's daily loss of 1.52%. Meanwhile, the Dow experienced a drop of 1.56%, and the technology-dominated Nasdaq saw a decrease of 1.78%.
The stock of company has risen by 55.06% in the past month, leading the Medical sector's loss of 3.1% and the S&P 500's loss of 2.25%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of $0.02, down 90% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $621.4 million, indicating a 6.04% upward movement from the same quarter last year.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of $0.53 per share and revenue of $2.81 billion. These results would represent year-over-year changes of 0% and +19.8%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 14.51% lower. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #3 (Hold).
Looking at valuation, Hims & Hers Health, Inc. is presently trading at a Forward P/E ratio of 49.21. For comparison, its industry has an average Forward P/E of 21.99, which means Hims & Hers Health, Inc. is trading at a premium to the group.
Investors should also note that HIMS has a PEG ratio of 2.45 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.19 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 146, positioning it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HIMS in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
In the latest close session, Hims & Hers Health, Inc. (HIMS - Free Report) was down 7.88% at $23.84. This change lagged the S&P 500's daily loss of 1.52%. Meanwhile, the Dow experienced a drop of 1.56%, and the technology-dominated Nasdaq saw a decrease of 1.78%.
The stock of company has risen by 55.06% in the past month, leading the Medical sector's loss of 3.1% and the S&P 500's loss of 2.25%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of $0.02, down 90% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $621.4 million, indicating a 6.04% upward movement from the same quarter last year.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of $0.53 per share and revenue of $2.81 billion. These results would represent year-over-year changes of 0% and +19.8%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 14.51% lower. As of now, Hims & Hers Health, Inc. holds a Zacks Rank of #3 (Hold).
Looking at valuation, Hims & Hers Health, Inc. is presently trading at a Forward P/E ratio of 49.21. For comparison, its industry has an average Forward P/E of 21.99, which means Hims & Hers Health, Inc. is trading at a premium to the group.
Investors should also note that HIMS has a PEG ratio of 2.45 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical Info Systems stocks are, on average, holding a PEG ratio of 1.19 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 146, positioning it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HIMS in the coming trading sessions, be sure to utilize Zacks.com.